Accessibility Menu
Aft Pharmaceuticals logo

Aft Pharmaceuticals(ASX) AFP

Market CapA$320.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)+34%
5 Year-6%
1 Year+59%
1 Month+21%
A$3.87
+0.26%
+0.01Today
Aft Pharmaceuticals last closing stock price
MetricPriceDate
Last closeAUD 3.872026-08-12
Aft Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.78%AUD 3.942026-08-05
1 month+21.32%AUD 3.192026-07-13
3 month+23.82%AUD 3.132026-05-14
Year to date+30.01%AUD 2.982025-12-30
1 year+59.19%AUD 2.432025-08-12
3 year+16.8%AUD 3.312023-07-31
5 year-6.39%AUD 4.132021-08-13
Since inception+34.25%AUD 2.882016-01-11

Aft Pharmaceuticals Financials at a Glance

Market Cap

A$320.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

NZ$462.82M

Net Income (TTM)

NZ$26.75M

EPS (TTM)

A$0.12

P/E Ratio

24.94

Dividend

A$0.02

Beta (Volatility)

-0.04 (Low)

Price

A$3.87

Volume

0

Open

A$3.87

Previous Close

A$3.87

Daily Range

A$3.87 - A$3.87

52-Week Range

A$2.20 - A$4.13

Estimated Earnings Date

Nov 19, 2026

AFP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aft Pharmaceuticals

AFT Pharmaceuticals Limited is a New Zealand-based company engaged in the complete lifecycle of pharmaceutical products, from development to distribution. Established in 1997, the company operates in various international markets, including Australia and Asia, offering a diverse range of healthcare solutions.

Products and Services
  • Pharmaceutical treatments for allergies and cold symptoms
  • Ophthalmic products and first aid solutions
  • Medicated vitamin supplements and digestive health products
Growth Outlook
  • Recent quarterly revenue reached NZD 140.78 million, showing strong market demand
  • Net income for the latest quarter was NZD 11.52 million, indicating profitability
  • Expansion into Asian markets is expected to drive future revenue growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of NZD 511.5 million reflects consistent performance
  • Operating income margin improved to 13.9% in the latest quarter
  • Current ratio of 2.24 indicates strong liquidity position
AFT Pharmaceuticals Limited has established itself as a key player in the pharmaceutical industry, with a focus on innovative healthcare solutions. The company's diverse product offerings cater to various health needs, positioning it well for future growth. Recent financial performance highlights a solid revenue base and profitability, which may attract potential investors looking for opportunities in the healthcare sector. The company's strategic expansion into new markets further enhances its growth potential, making it a noteworthy consideration for those interested in the pharmaceutical industry.
AI Generated • Aug 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

126

CEO

Hartley Atkinson, PhD

Website

www.aftpharm.com

Headquarters

Auckland, AUK 0622, NZ

AFP Financials

Key Financial Metrics (TTM)

Gross Margin

43.40%

Operating Margin

9.76%

Net Income Margin

5.78%

Return on Equity

14.07%

Return on Capital

15.12%

Return on Assets

6.79%

Earnings Yield

4.01%

Dividend Yield

0.66%

Payout Ratio

12.81%

Stock Overview

Market Cap

A$320.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

104.88M

Volume

0

Avg. Volume

3.11K

Financials (TTM)

Gross Profit

NZ$202.31M

Operating Income

NZ$42.60M

EBITDA

NZ$48.55M

Operating Cash Flow

NZ$1.35M

Capital Expenditure

-NZ$396.86K

Free Cash Flow

NZ$953.01K

Cash & ST Invst.

NZ$10.31M

Total Debt

NZ$54.50M

Aft Pharmaceuticals Performance Analysis

Aft Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31NZD 142,730,46716.2%
20242024-03-31NZD 181,155,05126.9%
20252025-03-31NZD 189,359,9434.5%
20262026-03-31NZD 226,329,92519.5%
Aft Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30-22.4%
Q42025-03-3139.9%
Q22025-09-30-6.0%
Q42026-03-3123.5%
Aft Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31NZD 0.09-48.2%
20242024-03-31NZD 0.1449.0%
20252025-03-31NZD 0.10-24.8%
20262026-03-31NZD 0.1220.2%
Aft Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30-116.7%
Q42025-03-31800.0%
Q22025-09-30-77.8%
Q42026-03-31253.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

NZ$140.78M

+25.9%

Gross Profit

NZ$61.30M

+17.1%

Gross Margin

43.55%

N/A

Market Cap

A$320.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.55M

N/A

Employees

126

N/A

Net Income

NZ$11.52M

-16.5%

EBITDA

NZ$21.52M

+0.9%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

NZ$10.31M

-14.3%

Total Debt

NZ$54.50M

+69.3%

Accounts Receivable

NZ$64.70M

+57.8%

Inventory

NZ$74.61M

+52.1%

Long Term Debt

NZ$41.90M

+33.5%

Short Term Debt

NZ$12.60M

+726.2%

Return on Assets

6.79%

N/A

Return on Invested Capital

16.50%

N/A

Free Cash Flow

-NZ$11.27M

-152.8%

Operating Cash Flow

-NZ$11.22M

-152.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TTX.AXTetratherix Ltd.
A$6.50-8.45%
MVF.AXMonash IVF Group Limited
A$0.70+0.72%
MYX.AXMayne Pharma Group Limited
A$3.24-0.92%
OCC.AXOrthocell Limited
A$0.79-0.63%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.56+0.02%
CDECoeur Mining
$18.45-0.02%
TAT&T
$24.58+0.01%
SMRNuScale Power
$9.85+0.03%

Questions About AFP

What is the current price of Aft Pharmaceuticals?

Aft Pharmaceuticals is trading at A$3.87 per share.

What is the 52-week range for Aft Pharmaceuticals?

Over the past 52 weeks, Aft Pharmaceuticals has traded between A$2.20 and A$4.13.

How much debt does Aft Pharmaceuticals have?

As of the most recent reporting period, Aft Pharmaceuticals reported total debt of NZ$45.07M.

How much cash does Aft Pharmaceuticals have on hand?

Aft Pharmaceuticals reported NZ$8.53M in cash and cash equivalents in its most recent financial results.

What is Aft Pharmaceuticals’s dividend yield?

Aft Pharmaceuticals currently has a dividend yield of 0.66%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services